Atopic dermatitis in children: management of pruritus.
Children with chronic atopic dermatitis (AD)-related itch require a comprehensive treatment approach that addresses the underlying cause of pruritus, as well as symptoms and complications that extend beyond the physical domain. In small children and infants, the short-term complications of quality of life disturbance and sleep dysfunction are closely associated with the course of adolescent development. In addition, the physical damage that results from uncontrolled pruritus and scratching can lead to disease chronification. Therefore, the rapid relief of acute pruritic flares, followed by the long-term maintenance of symptom-free skin, should be prioritized in AD treatment, in an effort to avoid the emotional, social and physical chronic manifestations described above. Alleviation of AD symptoms with fourth-generation topical anti-inflammatory agents like methylprednisolone aceponate is an appropriate choice of therapy for children and infants, due to its optimized therapeutic index and versatility in formulation. Especially in AD, supplemental disease management education should be considered, to address the psycho-social needs of children (and their families) suffering from pruritus.
Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Germany. ulrike.blume-peytavi@charite.de
U
U
Blume-Peytavi
M
M
Metz
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002648:Child; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008775:Methylprednisolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011537:Pruritus / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D012890:Sleep
D000893:Anti-Inflammatory Agents; C078007:methylprednisolone aceponate; D008775:Methylprednisolone